Biotech Shares Soar After AstraZeneca Stake & Research Collaboration - InvestingChannel

Biotech Shares Soar After AstraZeneca Stake & Research Collaboration

A Paris-based healthcare company saw an insanely bullish session on Wednesday after it was announced that AstraZeneca (Nasdaq:AZN) said it will acquire a stake in the company and enter into research collaboration, according to a press release.

Shares of Cellectis A.A. (Nasdaq:CLLS) went soaring on the news, with shares of this small cap reaching $2.99/share (+208.25%) at the session high. This move erased the majority of the losses this stock saw this summer. 

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body’s immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company’s gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

]]>

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire